#United States #Los Angeles #Securities Fraud #FDA #Capricor Therapeutics

Investigation into Capricor Therapeutics, Inc. (CAPR) for Securities Fraud

On July 29, 2026, Glancy Prongay Wolke & Rotter LLP, a prominent law firm focused on shareholder rights, announced an investigation regarding allegations of securities fraud against Capricor Therapeutics, Inc. (NASDAQ: CAPR). This comes after the release of negative briefing documents from the U.S. Food and Drug Administration (FDA) related to deramiocel, a cell therapy targeting Duchenne muscular dystrophy (DMD).

Background on the Situation

The investigation is prompted by concerns raised by the FDA in their briefing documents, which were released ahead of an advisory committee meeting regarding Capricor's cell therapy. The FDA questioned the company's methodology in measuring the therapy's results from its late-stage trial. They indicated that Capricor's approach to data measurement—converting raw changes to percent changes and back was scientifically unsound. Such practices, according to the FDA, complicate integrity and accuracy in clinical data reporting.

Moreover, the FDA's documents stated that the overall benefit-risk assessment for deramiocel appears to be unfavorable, largely due to a lack of compelling evidence supporting its effectiveness. This critical feedback raised alarms not only within the medical community but also among investors in Capricor Therapeutics.

Market Reaction and Price Decline

The initial reaction from the market was swift and severe. Following the FDA's disclosure, on July 27, 2026, Capricor’s share price plummeted by $12.70, which corresponds to a staggering 64.5% drop, closing at $7.00. This drastic decline has understandably agitated shareholders who invested in Capricor based on more optimistic outlooks prior to the FDA’s revelations.

Additional fallout occurred after the tissue and gene therapies advisory committee meeting held on July 29, where the FDA continued to express caution regarding deramiocel. Following this meeting, Capricor's stock further declined by $0.42 to close at $6.57, signaling ongoing unease among investors.

Call for Action

Given this backdrop, Glancy Prongay Wolke & Rotter LLP is urging shareholders who sustained losses to come forward. The firm is looking for individuals who wish to explore potential claims for recovery by participating in the investigation.

Glancy Prongay Wolke & Rotter LLP is recognized for its robust track record in representing investors in complex securities litigation. They encourage anyone affected to inquire about their rights and potential actions by contacting the firm directly.

For more detailed inquiries or participation in the case, affected shareholders can reach out to Charles Linehan, Esq. at [email protected] or call 310-201-9150 (Toll-Free: 888-773-9224).

Final Remarks

The situation regarding Capricor Therapeutics serves as a crucial reminder about the importance of transparency and accuracy in pharmaceutical reporting and trials. As this investigation unfolds, the outcomes will likely have lasting implications not only for Capricor and its stakeholders but also for broader discussions on regulatory oversight in drug approval processes. The stakes are high, and investors are advised to stay updated on developments in this case.